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Vancomycin Dosing in ESRD with 
Intermittent Hemodialysis (IHD)
Bilal Ahmad, DPIC Pharmacist
Due to its poor dialyzibility via low flux membranes, dose adjustment of Vancomycin 
is complicated in IHD. Prehemodialysis Vancomycin levels are a good predictor 
to define the maintenance doses, administered preferably after dialysis session. 
Loading dose (weight based has good clinical outcomes compared to fixed dosing 
regimen) is followed by post dialysis dose and withdrawal of levels before second 
dialysis session, subsequent dosing are based on Vancomycin levels. There is no 
validated guideline for dosing but AJHP recommended the following strategy.
Dosing in mild-moderate Dosing in severe Infections.
Loading Dose Algorithm
Actual body weight, kg Vancomycin LD (15-20mg/kg)
<65 1000mg IV
65.1 – 85 1250mg IV
85.1 – 100 1500mg IV
>100 1750mg IV
Maintenance dose algorithm
Serum Vancomycin Conc, mcg/mL MD after dialysis
<10 1000mg IV
10-15 500-750mg IV 
15.1- 20 500mg IV
>20 Hold Vancomycin
Loading Dose Algorithm
Actual body weight, kg Vancomycin LD (20mg/kg)
<65 1000mg IV
65.1 – 85 1500mg IV
85.1 – 100 1750mg IV
>100 2000mg IV
Maintenance dose algorithm
Serum Vancomycin Conc, mcg/mL MD after dialysis
<10 1gm-1.5gm IV
10-15 750-1000mg IV
15.1- 20 500-750MG IV
>20 500mg IV
>25 Hold Vancomycin
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Increased Risk of Ventricular Arrhythmias 
with Domperidone 
Muhammad  Amir, Specialist 
Increased risk of serious ventricular arrhythmias or sudden cardiac death have 
been associated with the use of Domperidone.  Risk is increased particularly with 
doses >30 mg, geriatrics , children and with drug causing QT elongation and CYP 
3A4 interacting drugs.  To reduce the risk 
1. In adults and children aged ≥ 12 years old weighing ≥ 35 kg, the 
 recommended maximum oral daily dose is 30 mg, given in doses of 10 mg 
 up to three times daily
2. Children aged < 12 years old and those aged ≥ 12 years old weighing < 35 
 kg, the recommended dose is 0.25 mg/kg orally up to three times daily. For   
Reference:              
 Page Crew, Shannon J. Heintz, Brett H. Heintz, Vancomycin dosing and monitoring for patients with end-
 stage renal disease receiving intermittent hemodialysis, American Journal of Health-System Pharmacy, 
 Volume 72, Issue 21, 1 November 2015, Pages 1856–1864,
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 rectal administration, these patients may also be given 0.75 mg/kg twice 
 daily as suppositories.
3. Use the lowest possible dose for the shortest duration necessary.
4. Avoid drugs causing QT elongation or CYP 3A4 inhibition or induction
References:
 1 Health Science Authority. New recommendations on the use of domperidone. 
 https://www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Safety_Information_and_Product_Recalls/Product_Safety_Alerts/2017/new-recommendati 
 onsontheuseofdomperidone.html
Drug Induced Esinophilic Pneumonia 
Nida Abbasi, Clinical Pharmacist
Eosinophilic pneumonia (EP) is a rare and heterogeneous syndrome, also known as pulmonary infiltrates with eosinophilia 
syndrome. Drugs known to cause eosinophilic pneumonia are  gemcitabine, infliximab, ranitidine, sulfasalazine/
mesalamine, venlafaxine  As per the hypothesized mechanism, drug increased concentration results in the retention of in 
the alveoli leading to continuous activation of immune system. Further studies are required to understand this phenomena. 
In order to treat Drug induced EP, corticosteroids are suggested for use, as they may cause eosinophilic apoptosis. As a 
common regimen intravenous methylprednisolone is recommended as 60–125 mg every 6 h, with conversion to prednisone 
40–60 mg oral daily and taper over 2–6 weeks.
References:
 1.  Higashi Y, Nakamura S, Tsuji Y, et al. Daptomycin-induced Eosinophilic Pneumonia and a Review of the Published Literature. Intern Med. 2018;57(2):253– 
  258. doi:10.2169/internalmedicine.9010-17
	 2.	Yang	Ye,	Zijing	Xia,	Dan	Zhang,	et	al.,	“Multifunctional	Pharmaceutical	Effects	of	the	Antibiotic	Daptomycin,”	BioMed	Research	International,	vol.	2019,		
  Article ID 8609218, 9 pages, 2019. https://doi.org/10.1155/2019/8609218.
 3. Priyasha Uppal, Kerry L. LaPlante, Melissa M. Gaitanis, Matthew D. Jankowich,Kristina E. Ward, Daptomycin-induced eosinophilic pneumonia - a  
  systematic review, Antimicrobial Resistance & Infection Control, 2016, Volume 5, Number 1, Page 1
An Insight on aspirin; ASCEND, ARRIVE and ASPREE Trials
Syeda Anum Fatima, IPD Pharmacist.
Up till now meta-analysis on using low-dose-aspirin suggested benefit in preventing cardiovascular events, reducing all-
cause mortality and even reduction in colon cancer risk. However, three major RCT’s in 2018 have concluded otherwise. 
The first trial known as the ‘ASCEND’ evaluated the role of aspirin in 15,480 diabetic patients concluding that there 
might be some benefit associated with the reduction in CVS events in diabetics but there was increase in the major 
bleeding events is aspirin groups as compared with the placebo with most patients experiencing gastrointestinal and other 
extracranial bleeding events. Another important highlight of this trial was that there was no significant difference between 
the aspirin and placebo groups with respect to G.I or other cancers. The second trial known as the ‘ARRIVE’ study to 
evaluated the use of aspirin in patients who were at moderate risk of CVS events, this study published data based on 13000 
patients and concluded that aspirin had no effect in reducing all-cause mortality or CVS events as primary endpoints, there 
was a slight increase in G.I bleeding events in the aspirin groups as compared to the placebo. The third trial known as the 
‘ASPREE’ trial evaluated 20000 patients for aspirin effect on All-cause mortality in healthy elderly patients. The findings 
of this large RCT was different from the other two as All-cause mortality in the aspirin group was 12.7% while in the 
placebo group was 11.1% with cancer being the major contributor for death i.e. 3.1% in the aspirin group while 2.3% in 
the placebo group. With these three major RCTs clinicians need to be careful about using aspirin as primary prevention 
for CVS events but we must keep in mind that this does not have to do anything with the use of aspirin for secondary 
prevention as the evidence for latter is definite with benefit outweighing the risks.
Reference: 
 Kuehn BM. Aspirin for Primary Prevention Takes a Hit With New Trial Results. Circulation. 2018 Dec 4;138(23):2713-2714.
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Drugs Administeration Through Nasogastric Tube (Advantages and 
Its Restrictions) 
Saba Jawed, In-patient Pharmacist
 
Enteral feeding tube is mostly used in those patients that are critically ill and cannot take solid diet. Before administration, 
following parameters should be considered via enteral tube like drug formulation, type of tube, interaction with feed and 
site of drug absorption.
FORMULATION TO BE ADMINSTERATED VIA NG TUBE:
Liquid Dosage Form: Many drug formulations available in both solid and liquid form are easily administered but some 
are not commercially available. But can be prepared. Available liquid preparations should be diluted enough to be used 
via NG because some are very thick and viscous preparations.
Solid Dosage Form: Some tablets/capsules are used through NG by crushing them or in powder form. Dilute enough to 
easily administer (mostly 30-50 ml WFI). Sugar coated and film coated can also be used except enteric/ controlled release 
tablets/capsules/ buccal/sublingual/ cytotoxic drugs because of increase risk of adverse drug reactions.
Parenteral: Some IV preparations given orally can be given  through  NG tube.
Following drugs have interaction with enteral feed like Carbamazepine, Hydralazine, Ciprofloxacin, Thyroxine, Warfarin 
and Phenytoin sodium leading to decreased absorption, it may adhere to tubing. 
Following drugs are easily administered:
References:
 American Parkinson’s Disease Association, APDA
FDA Box Warning | Opioid- Withdrawal Symptoms
Hafsa Ghalib, Pharmacist
US FOOD AND DRUG ADMINISTRATION, notified about the serious harm in patients physically dependent on 
opioid pain medicines, with the sudden discontinuation or rapid decrease in their dose. These include serious withdrawal 
symptoms of uncontrolled pain, psychological distress, and suicide. These symptoms can cause patients to seek other 
sources of opioid pain medicines, which can be confused with drug seeking for abuse. Patient may attempt to treat their 
pain and symptoms with illicit opioids, such as heroin, and other substances.
RECOMMENDATIONS FOR HEALTH CARE PROFESSIONALS:
 i. Health care professionals should not abruptly discontinue opioids in physically dependent patients.
 ii. Dose of opioids analgesics should be tapered based on factors, including the dose of the drug, the duration of 
  treatment, the type of pain being treated, and the physical and psychological attributes of the patient.
 iii. No standard opioid tapering schedule exists that is suitable for all patients.
 iv. Create a patient-specific plan to gradually taper the dose and ensure ongoing monitoring and support to avoid 
  serious withdrawal effects.
Reference: 
 FDA Drug Safety Communication (April 9, 2019)
 https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes
3
 Acetazolamide
Bromocriptine
Amoxicillin
Clopidogrel
Amlodipine
Valsartan
 Atenolol
Septran
Amitriptyline
Aspirin 
(non enteric)
Amiodarone
Vancomycin
 Baclofen
Pyridoxine Perindopril
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The Aga Khan University Hospital, Karachi
Provide us your Valuable Feedback!
To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful 
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an 
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu 
Thank you in advance for your feedback! 
Link: https://goo.gl/forms/Ghh1Nc2KY2jEkiUL2
Warning | Fluoroquinolone use Associated with Aortic Aneurysm 
Nida Abbasi, Clinical Pharmacist
Recently FDA has issued warning that fluoroquinolones use is associated with aortic aneurysm. It was identified after a 
review of cases reported in FDA adverse event reporting system. The findings from the observational studies confirm the 
positive association between fluoroquinolone and the development of aortic aneurysm/ dissection, hence suggested to 
avoid fluoroquinolone in patients with known aortic aneurysms or those with risk factors for aneurysm such as Marfan’s 
syndrome, Ehlers-Danlos syndrome, peripheral atherosclerotic vascular diseases, hypertension, and/or advanced age. 
Although exact mechanism is unknown, but there are several possibilities. Fluoroquinolone destroy the collagen and 
connective tissue along the aortic wall causing aortic aneurysm and dissection as they do on tendon and cornea. Moreover, 
some risk factors may appear to prevail including prolonged fluoroquinolone treatment and older age.
The FDA offers the following advice for the physicians:
 l Do not prescribe fluoroquinolone to those patients who are with aortic aneurysm or are at the risk of developing 
  it, except if there is no any alternative. 
 l Advice all patients to seek immediate medical attention if they develop symptoms of aortic aneurysm.
 l Stop fluoroquinolone immediately if patients have symptoms of aortic aneurysm or dissection.
References:
	 US	Food	and	Drug	Administration.	Fluoroquinolone	Antibiotics:	Safety	Communication	-	Increased	Risk	of	Ruptures	or	Tears	in	the	Aorta	Blood	Vessel	in	
 Certain Patients. 
Medications to Be Avoided or Used with Caution in Parkinson’s 
Disease |APDA 
Bilal Ahmad, DPIC Pharmacist
Medication Type Medication Name
Narcotics/Analgesics Meperidine Tramadol Methadone Propoxyphene
Antidepressants St. John’s Wort
Muscle Relaxants Cyclobenzaprine
Cough Suppressants Dextromethorphan
Decongestants/Stimulants Pseudoephedrine Phenylephrine Ephedrine
Other medications that inhibit 
Monoamine oxidase Linezolid (antibiotic) Phenelzine Tranylcypromine Isocarboxazid
Medications to be avoided or used with caution in all patients with Parkinson’s disease
Typical Antipsychotics Chlorpromazine Fluphenazine Haloperidol Trifluoperazine (Block D2 (dopamine) receptors in the brain, which can worsen Parkinson’s )symptoms
Atypical Antipsychotics
Risperidone Olanzapine Ziprasidone Aripiprazole Lurasidone Paliperidone (Block dopamine receptors, but dissociate from the recep- tor more 
quickly than typical antipsychotics. They also tend to block serotonin receptors in addition to dopamine recep- tors. The result is less parkin- sonism 
than that caused by the typical antipsychotics).
Antiemetic (used to treat nausea 
or vomiting)
Chlorpromazine Droperidol Metoclopramide Prochlorperazine Promethazine (Block D2 (dopamine) receptors in the brain, which can worsen Parkin-
son’s symptoms).
Drugs to treat hyperkinetic 
movements such as chorea and 
tardive dyskinesia
Tetrabenazine Deutetrabenazine Valbenazine (Decrease dopamine stores)
Antihypertensives Reserpine (Decreases dopamine stores)
Methyldopa (Inhibits an enzyme which converts L-dopa into dopamine in the brain)
Antidepressants Phenelzine Tranylcypromine Isocarboxazid (Block monoamine oxidase non-selectively. If taken in combination with certain classes of PD meds, 
these medications could result in dangerous increases in blood pressure and agitation).
Amoxapine (Although classified as a tricyclic anti-depressant, it can also block dopamine receptors)
Medications to be avoided or used with caution in combination with Selegiline & Rasagiline.
